Novo Nordisk, Eli Lilly and the GLP-1 economy
Unhedged
00:00
Navigating the GLP-1 Drug Landscape
This chapter examines the competitive dynamics between pharmaceutical giants Eli Lilly and Novo Nordisk in the GLP-1 drug market, particularly focusing on financial implications, regulatory challenges, and emerging competition. It highlights the upcoming changes in the market due to patent expirations and the potential shift towards oral medications, shaping the strategies necessary for maintaining their market positions.
Transcript
Play full episode
